Boehringer Ingelheim Licenses Zealand Pharma’s Drug Candidates for Type 2 Diabetes and Obesity

By Heather Cartwright

Pharma Deals Review: Vol 2011 Issue 6 (Table of Contents)

Published: 21 Jun-2011

DOI: 10.3833/pdr.v2011.i6.1485     ISSN: 1756-7874

Section: Licensing



Boehringer Ingelheim has licensed the global rights to Zealand Pharma’s dual-acting glucagon and GLP-1 (glucagon-like peptide-1) agonists for the treatment of type 2 diabetes and obesity...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details